Maxim analyst Jason McCarthy upgraded Coherus Biosciences (CHRS) to Buy from Hold.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Oncology’s Earnings Call Highlights Growth and Challenges
- Coherus Biosciences: Buy Rating Affirmed Amid Strong Sales Alignment and Promising Pipeline Developments
- Coherus Biosciences: Promising Growth and Strategic Positioning Justify Buy Rating
- Coherus Oncology Reports Strong Q2 2025 Growth
- Coherus Biosciences reports Q2 EPS (39c), consensus (27c)